Neuroimaging Biomarkers for Schizophrenia

Clinicians need reliable and valid biomarkers to prevent and treat illnesses effectively. This has been challenging within psychiatry. However, today’s neuroimaging tools have significantly progressed the development of clinically applicable biomarkers.

Jose M. Rubio M.D., Ph.D.
Institute for Behavioral Science, Feinstein Institute of Medical Research - Northwell Health, Manhasset, NY, USA
Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, Hempstead, NY, USA
Division of Psychiatry Research - Zucker Hillside Hospital - Northwell Health, 75-59 26, 3rd st, Glen Oaks, NY 11004, USA

Chapters:
00:00 - Why do we need biomarkers for Schizophrenia?
01:55 - Why don't we already have biomarkers for Schizophrenia?
03:25 - What is necessary to bring biomarkers to the psychiatric clinic?
06:19 - What is the current state of developing biomarkers in Schizophrenia?
07:26 - Why are the current biomarkers focusing specifically on the striatial function?
08:16 - Development of neuroimaging biomarkers for Schizophrenia. Resting-state fMRI, fALFF, SCI, FSA
12:58 - Why are these biomarkers important?
14:05 - What is next?